Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lessons From the EThIGII Trial: Proper Putative Benefit Assessment of Low-Molecular-Weight Heparin Treatment in M2/ANXA5 Haplotype Carriers.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis - 1 Jan 2017

Rogenhofer Nina, Markoff Arseni, Wagner Annett, Klein Hanns-Georg, Petroff David, Schleussner Ekkehard, Thaler Christian J

Abstract excerpt

This study presents sample size considerations derived from the Efficacy of Thromboprophylaxis as an Intervention during Gravidity (EThIGII) trial (ClinicalTrials.gov: NCT00400387) to address the question of low-molecular-weight heparin (LMWH) treatment in women with recurrent pregnancy loss (RPL) depending on the M2/ANXA5 haplotype. To evaluate the possible influence of such treatment on miscarriage rates of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Abortion, Habitual
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Haplotypes

Share to Risk Factors

Source

Identifiers

PMID: 27418639
DOI: 10.1177/1076029616658117

Genes

ANXA5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lessons From the EThIGII Trial: Proper Putative Benefit Assessment of Low-Molecular-Weight Heparin Treatment in M2/ANXA5 Haplotype Carriers.PMID 27418639Read ↗

ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia--study protocol for a randomized controlled trial.Semantic proximity Read ↗

Further insights into the role of the annexin A5 M2 haplotype as recurrent pregnancy loss factor, assessing timing of miscarriage and partner risk.Semantic proximity Read ↗

Precision Medicine in Assisted Conception: A Multicenter Observational Treatment Cohort Study of the Annexin A5 M2 Haplotype as a Biomarker for Antithrombotic Treatment to Improve Pregnancy OutcomeSemantic proximity Read ↗

Haplotype M2 in the annexin A5 (ANXA5) gene and the occurrence of obstetric complicationsSemantic proximity Read ↗

Genetic analysis of ANXA5 haplotype and its effect on recurrent pregnancy loss.Semantic proximity Read ↗

Genetic markers for inherited thrombophilia related pregnancy loss and implantation failure in Indian population - implications for diagnosis and clinical management.Semantic proximity Read ↗

Genetic evidence for causal associations of thrombohemostasis and anticoagulant drug targets with miscarriage.Semantic proximity Read ↗

Independent association of the M2/ANXA5 haplotype with recurrent pregnancy loss (RPL) in PCOS patients.Semantic proximity Read ↗

“Unraveling the Clot-Miscarriage Nexus: Mechanisms, Management, and Future Directions in Thrombosis-Related Recurrent Pregnancy Loss”Semantic proximity Read ↗

Assessment of M2/ANXA5 haplotype as a risk factor in couples with placenta-mediated pregnancy complications.Semantic proximity Read ↗

Research progress on ANXA5 in recurrent pregnancy loss.Semantic proximity Read ↗

Pregnancy loss and thrombophilia: the elusive linkSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.